464 related articles for article (PubMed ID: 26198708)
1. 'Micro-managers' of hepatic lipid metabolism and NAFLD.
Liu W; Cao H; Yan J; Huang R; Ying H
Wiley Interdiscip Rev RNA; 2015; 6(5):581-93. PubMed ID: 26198708
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1.
Zhang M; Sun W; Zhou M; Tang Y
Sci Rep; 2017 Nov; 7(1):14493. PubMed ID: 29101357
[TBL] [Abstract][Full Text] [Related]
4. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
Geisler CE; Renquist BJ
J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Fang Z; Dou G; Wang L
Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
[TBL] [Abstract][Full Text] [Related]
6. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD.
Latorre J; Moreno-Navarrete JM; Mercader JM; Sabater M; Rovira Ò; Gironès J; Ricart W; Fernández-Real JM; Ortega FJ
Int J Obes (Lond); 2017 Apr; 41(4):620-630. PubMed ID: 28119530
[TBL] [Abstract][Full Text] [Related]
7. Molecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASH.
Wang Y; Liu Z; Zou W; Hong H; Fang H; Tong W
Biomark Med; 2015; 9(11):1189-200. PubMed ID: 26506944
[TBL] [Abstract][Full Text] [Related]
8. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
Zhuge B; Li G
Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease.
Liu XL; Cao HX; Fan JG
J Dig Dis; 2016 Nov; 17(11):708-715. PubMed ID: 27628945
[TBL] [Abstract][Full Text] [Related]
10. Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease.
Torres JL; Novo-Veleiro I; Manzanedo L; Alvela-Suárez L; Macías R; Laso FJ; Marcos M
World J Gastroenterol; 2018 Sep; 24(36):4104-4118. PubMed ID: 30271077
[TBL] [Abstract][Full Text] [Related]
11. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis.
Leti F; Malenica I; Doshi M; Courtright A; Van Keuren-Jensen K; Legendre C; Still CD; Gerhard GS; DiStefano JK
Transl Res; 2015 Sep; 166(3):304-14. PubMed ID: 26001595
[TBL] [Abstract][Full Text] [Related]
12. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Steatosis as a Marker of Metabolic Dysfunction.
Fabbrini E; Magkos F
Nutrients; 2015 Jun; 7(6):4995-5019. PubMed ID: 26102213
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH.
Amrutkar M; Cansby E; Nuñez-Durán E; Pirazzi C; Ståhlman M; Stenfeldt E; Smith U; Borén J; Mahlapuu M
FASEB J; 2015 Apr; 29(4):1564-76. PubMed ID: 25609431
[TBL] [Abstract][Full Text] [Related]
15. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
Xi Y; Li H
Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
[TBL] [Abstract][Full Text] [Related]
16. miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease.
Auguet T; Aragonès G; Berlanga A; Guiu-Jurado E; Martí A; Martínez S; Sabench F; Hernández M; Aguilar C; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669236
[TBL] [Abstract][Full Text] [Related]
17. Innate immune regulatory networks in hepatic lipid metabolism.
Bai L; Li H
J Mol Med (Berl); 2019 May; 97(5):593-604. PubMed ID: 30891617
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1.
Zhang M; Tang Y; Tang E; Lu W
Biochem Biophys Res Commun; 2020 Apr; 524(3):716-722. PubMed ID: 32035613
[TBL] [Abstract][Full Text] [Related]
19. Steroidogenic acute regulatory protein (StAR) overexpression attenuates HFD-induced hepatic steatosis and insulin resistance.
Qiu Y; Sui X; Zhan Y; Xu C; Li X; Ning Y; Zhi X; Yin L
Biochim Biophys Acta Mol Basis Dis; 2017 Apr; 1863(4):978-990. PubMed ID: 28153708
[TBL] [Abstract][Full Text] [Related]
20. miR-26a Potentially Contributes to the Regulation of Fatty Acid and Sterol Metabolism In Vitro Human HepG2 Cell Model of Nonalcoholic Fatty Liver Disease.
Ali O; Darwish HA; Eldeib KM; Abdel Azim SA
Oxid Med Cell Longev; 2018; 2018():8515343. PubMed ID: 30402207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
